The FDA Total Product Life Cycle Advisory Program (TAP) is reshaping how innovative medical devices move from concept to commercial success. Designed to support breakthrough-designated and Safer Technologies Program participants, the FDA TAP program goes beyond traditional regulatory interactions by aligning regulatory strategy with reimbursement, clinical adoption, and patient access early in product development.
What is the FDA TAP Program?
TAP was introduced under the fifth revision of the Medical Device User Fee Amendment (MDUFA V) to support Sponsors of innovative medical devices across theentire product life cycle,from early concept development through post-market evidence generation and long-term adoption.
Unlike traditional FDA engagement models that are largely episodic and submission-driven, the FDA TAP program is intentionally designed to becontinuous, collaborative, and strategic. By engaging early in the development process and conducting frequent, focused interactions, TAP helps manufacturers make better development decisions earlier, when changes are less costly and flexibility is highest.
At its core, the TAP program is built on the recognition that regulatory authorization alone is rarely sufficient for commercial success. Devices that reach the market often encounter unexpected barriers related to reimbursement, clinical workflow integration, or stakeholder acceptance. By addressing these considerations earlier, the TAP program aims to reduce downstream risk and accelerate patient access to meaningful innovation.
Key goals of the FDA TAP program include:
- Supporting early and frequent engagement between Sponsors and FDA reviewers
- Encouraging alignment of evidence strategies across regulatory, payer, clinician, and patient needs
- Improving predictability and efficiency in development pathways
- Reducing delays between FDA authorization, reimbursement decisions, and real-world adoption
In practical terms, the TAP program shifts the development mindset from “regulatory-first” to “total product life cycle” planning.
Why the TAP Program Was Created
FDA leadership and industry stakeholders have long observed a recurring challenge in medical device innovation: many companies successfully obtain FDA clearance or approval, yet struggle to achieve reimbursement, clinical uptake, or sustainable commercialization.
Across the medical device industry, several recurring factors contribute to this disconnect between regulatory success and market adoption:
- Evidence generation plans that focus narrowly on regulatory endpoints
- Limited early engagement with payers and health technology assessment bodies such as professional societies and patient advocacy groups
- Insufficient consideration of real-world clinical workflows
- Late discovery of adoption barriers that require additional studies or design changes
The FDA TAP program was created to proactively address these challenges by bringing key stakeholders into the development conversation earlier. Rather than treating regulatory approval as the finish line, TAP reframes it as one milestone within a broader journey toward patient access and impact.
This approach reflects the FDA’s broader evolution toward lifecycle-based oversight and collaboration, recognizing the Sponsor’s perspective: that well-aligned development strategies ultimately benefit patients, providers, payers, and manufacturers alike.
Who is Eligible for the FDA TAP Program?
Core Eligibility Requirements
Participation in the FDA TAP program is limited to devices that meet specific eligibility criteria. At a minimum, a device must:
- Have Breakthrough Device Designation or be accepted into the Safer Technologies Program (STeP)
- Be in early-stage development, where strategic input can meaningfully influence design and evidence plans
- Be regulated by CDRH (the program is not currently available for combination products or CBER-regulated devices)
- Be limited to one TAP-enrolled device per Sponsor per fiscal year
Importantly, clinical data are not required at the time of enrollment. In fact, the program is intentionally structured to engage Sponsors before pivotal decisions are locked in.
Enrollment is first-come, first-served, and subject to annual participation caps defined by FDA resource availability.
Expanding Access to TAP
Since its initial soft launch in FY2023, the FDA TAP program has expanded steadily in both scope and accessibility. What began as a limited pilot focused on cardiovascular technologies has grown to include multiple clinical divisions, such as:
- Neurology
- Orthopedics
- Ophthalmology
- Radiological Health
The FDA has communicated its intention to continue expanding the program through FY2027, signaling long-term commitment to the TAP framework. For innovative device manufacturers, this expansion represents increasing opportunity to leverage the program across a wider range of therapeutic areas.
How the FDA TAP Program Works
Step 1: Enrollment
Once a Sponsor receives Breakthrough Device or STEP acceptance, they may request entry into the FDA TAP program through a Q-Submission amendment. The FDA reviews the request and typically provides confirmation and next steps within approximately 30 days.
Acceptance into TAP does not change the device’s regulatory classification or pathway. Instead, it enhances how the FDA and the Sponsor interact throughout development.
Step 2: TAP Engagement Plan
After acceptance, the FDA assigns a dedicated TAP Advisor who serves as a central coordination point. Together, the Sponsor and TAP Advisor develop a customized TAP Engagement Plan, which outlines priorities, milestones, and discussion topics across two parallel tracks:
- Quality & Regulatory Strategy (FDA-facing)
- Market Adoption & Patient Access Strategy (non-FDA stakeholders)
The Engagement Plan is not static. It evolves as the device progresses, new data emerges, and strategic questions arise, making TAP a flexible, adaptive framework rather than a one-time interaction.
FDA Interactions Under the TAP Program
One of the most practical benefits of the FDA TAP program is the ability to interact with the FDA more frequently and efficiently than through traditional pre-submission mechanisms.
Rather than relying solely on formal, infrequent submissions, TAP enables a range of interaction types, including:
- Touch-base meetings for informal alignment and strategy discussions
- Teleconferences with accelerated turn-around timelines (often around 14 days)
- Written feedback requests with shorter review cycles (typically ~40 days)
- Targeted discussions on specific topics such as biocompatibility, sterility, or clinical study design
These interactions are “regulatory sprints”, focused, time-bound conversations that allow Sponsors to validate assumptions and adjust course early, before issues escalate into costly delays.
What Makes the TAP Program Different: Non-FDA Stakeholder Engagement
What truly distinguishes the FDA TAP program from other FDA initiatives is its structured support for engagement with non-FDA stakeholders. While the FDA does not represent these groups, the TAP framework helps Sponsors identify and connect with them at the right time.
Payers and Reimbursement Experts
Early engagement with payers can clarify expectations around:
- Coding, coverage, and payment pathways
- Evidence requirements for reimbursement decisions
- Health economic and outcomes data needs
This insight allows Sponsors to design studies that support both regulatory and reimbursement objectives, reducing the risk of post-authorization evidence gaps.
Professional Societies and Clinicians
Input from professional societies and practicing clinicians helps manufacturers understand:
- How a new device fits into existing clinical workflows
- Training or usability considerations
- Adoption barriers that may not be apparent from a regulatory perspective
Patient Organizations
Patient groups provide critical perspectives on:
- Benefit–risk tradeoffs
- Usability and access considerations
- Outcomes that matter most in real-world use
While the FDA may help facilitate initial connections with professional societies, clinicians, and patient organizations,Sponsors retain full ownership of meeting agendas, materials, and follow-up actions.
Real-World Impact of the FDA TAP Program
The FDA TAP program is designed to deliver practical, downstream impact by helping Sponsors make better decisions earlier in development, when design, evidence strategy, and market assumptions are still adaptable. Across the medical device industry, manufacturers leveraging TAP report clearer alignment across regulatory, clinical, and commercial objectives.
The real-world impact of the FDA TAP program lies in its ability to reduce uncertainty, improve development efficiency, and increase the likelihood that innovative medical devices achieve both regulatory success and sustainable market entry.
Earlier Strategic Clarity and Reduced Late-Stage Risk
By encouraging early discussion of intended use, indications, and clinical context, the FDA TAP program helps Sponsors avoid late-stage surprises that can trigger additional studies, design changes, or prolonged review cycles. Early alignment enables teams to streamline validation strategies, focus on clinically meaningful endpoints, and reduce rework as programs advance.
More Efficient Evidence Generation
TAP supports a more integrated approach to evidence planning by aligning regulatory requirements with the expectations of payers, clinicians, and patients. This coordination helps manufacturers:
- Design studies that support both FDA authorization and reimbursement decisions
- Anticipate post-market evidence needs earlier
- Reduce duplication across clinical, health economic, and usability studies
The result is a more efficient development pathway with fewer disconnected workstreams.
Improved IDE and Clinical Strategy Development
For devices requiring clinical investigation, the FDA TAP program can help Sponsors identify and address potential IDE challenges earlier. By incorporating clinical workflow considerations and patient perspectives into planning, manufacturers are better positioned to develop protocols that are feasible, relevant, and aligned with real-world use.
Stronger Market Readiness at Authorization
Devices developed under the TAP framework are often better prepared for the transition from authorization to adoption. Early engagement with non-FDA stakeholders helps clarify:
- Adoption barriers within clinical settings
- Training and usability considerations
- Evidence gaps that could delay coverage or uptake
This proactive approach reduces the common lag between FDA authorization and meaningful patient access.
Long-Term Value Across the Product Life Cycle
Rather than focusing solely on the next regulatory milestone, the FDA TAP program supports long-term thinking across the total product life cycle. Manufacturers that engage early are better positioned to manage post-market obligations, generate real-world evidence, and adapt their strategies as technologies and markets evolve.
Frequently Asked Questions (FAQs)
Is the FDA TAP program the same as the Breakthrough Device Program?
No. The Breakthrough Device Program focuses primarily on facilitating regulatory interactions. The FDA TAP program builds on that foundation by integrating payer, clinician, and patient perspectives earlier in development.
Does TAP replace FDA pre-submissions?
In many cases, TAP interactions serve as a faster, more iterative alternative to traditional pre-submissions, offering more frequent touchpoints and shorter feedback timelines.
Is FDA feedback under TAP binding?
As with pre-submissions, feedback provided under the TAP program is not legally binding. However, it is generally considered reliable when Sponsors act on it in a timely and transparent manner.
Does participating in TAP increase workload for Sponsors?
While the program requires preparation and strategic engagement, these activities reflect best practices Sponsors should already be pursuing to support long-term success.
When is the best time to enter the FDA TAP program?
There are several important differences in test methodology regarding summative simulated use tests compared to other usability evaluations such as formative testing. The summative test is not meant to be an exploratory effort seeking inputs on design features and should be performed on the final design of the device. It includes representative users, environments, and use scenarios and follows a structured, predefined protocol which focuses on critical tasks and worst-case conditions. The summative testing will be provided in a formal report for regulatory submission.
